The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-line pemetrexed plus cisplatin followed by maintenance pemetrexed versus carboplatin-paclitaxel plus bevacizumab followed by maintenance bevacizumab (ERACLE) in advanced nonsquamous NSCLC: A quality-of-life-oriented, multicenter randomized phase III trial of the GOIM (Gruppo Oncologico Italia Meridionale).
Domenico Galetta
No relevant relationships to disclose
Salvatore Pisconti
No relevant relationships to disclose
Saverio Cinieri
No relevant relationships to disclose
Vittorio Gebbia
No relevant relationships to disclose
Alessandro Morabito
No relevant relationships to disclose
Nicolo Borsellino
No relevant relationships to disclose
Evaristo Maiello
No relevant relationships to disclose
Antonio Febbraro
No relevant relationships to disclose
Annamaria Catino
No relevant relationships to disclose
Pietro Rizzo
No relevant relationships to disclose
Michele Montrone
No relevant relationships to disclose
Giovanni Simone
No relevant relationships to disclose
Vito Lorusso
No relevant relationships to disclose
Daniele Rizzi
No relevant relationships to disclose
Giovanni L. Pappagallo
No relevant relationships to disclose
Giuseppe Colucci
No relevant relationships to disclose